Topics

FDA Grants Priority Review to Clovis Oncology’s Rubraca for Treatment of Advanced Prostate Cancer

09:43 EST 17 Jan 2020 | Speciality Pharma Journal

BOULDER, Colo.–(BUSINESS WIRE)–Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) for Rubraca® (rucaparib) and granted priority review status to the application with a Prescription Drug User Fee Act (PDUFA) date of May 15, 2020. Clovis submitted the sNDA submission for …

Original Article: FDA Grants Priority Review to Clovis Oncology’s Rubraca for Treatment of Advanced Prostate Cancer

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Priority Review to Clovis Oncology’s Rubraca for Treatment of Advanced Prostate Cancer"

Quick Search

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...